Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347

J Immunol. 2004 Aug 15;173(4):2762-70. doi: 10.4049/jimmunol.173.4.2762.

Abstract

Inflammatory conversion of murine astrocytes correlates with the activation of various MAPK, and inhibition of terminal MAPKs like JNK or p38 dampens the inflammatory reaction. Mixed lineage kinases (MLKs), a family of MAPK kinase kinases, may therefore be involved in astrocyte inflammation. In this study, we explored the effect of the MLK inhibitors CEP-1347 and CEP-11004 on the activation of murine astrocytes by either TNF plus IL-1 or by a complete cytokine mix containing additional IFN-gamma. The compounds blocked NO-, PG-, and IL-6 release with a median inhibitory concentration of approximately 100 nM. This activity correlated with a block of the JNK and the p38 pathways activated in complete cytokine mix-treated astrocytes. Although CEP-1347 did not affect the activation of NF-kappaB, it blocked the expression of cyclooxygenase-2 and inducible NO synthase at the transcriptional level. Quantitative transcript profiling of 17 inflammation-linked genes revealed a specific modulation pattern of astrocyte activation by MLK inhibition, for instance, characterized by up-regulation of the anti-stress factors inhibitor of apoptosis protein-2 and activated transcription factor 4, no effect on manganese superoxide dismutase and caspase-11, and down-regulation of major inflammatory players like TNF, GM-CSF, urokinase-type plasminogen activator, and IL-6. In conclusion, MLK inhibitors like CEP-1347 are highly potent astrocyte immune modulators with a novel spectrum of activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / drug effects*
  • Astrocytes / enzymology
  • Astrocytes / immunology
  • Blotting, Western
  • Carbazoles / pharmacology*
  • Cells, Cultured
  • Cyclooxygenase 2
  • Dose-Response Relationship, Drug
  • Enzyme Activation / drug effects
  • Enzyme Activation / immunology
  • Enzyme Inhibitors / pharmacology*
  • Gene Expression / drug effects
  • Immunoassay
  • In Situ Hybridization
  • Indoles / pharmacology*
  • Inflammation / immunology*
  • Interleukin-6 / metabolism
  • Isoenzymes / drug effects
  • Isoenzymes / metabolism
  • JNK Mitogen-Activated Protein Kinases*
  • MAP Kinase Kinase 4
  • MAP Kinase Kinase Kinases / drug effects*
  • MAP Kinase Kinase Kinases / immunology
  • Mice
  • Mitogen-Activated Protein Kinase Kinases / drug effects
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • NF-kappa B / drug effects
  • NF-kappa B / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase / drug effects
  • Nitric Oxide Synthase / metabolism
  • Nitric Oxide Synthase Type II
  • Polymerase Chain Reaction
  • Prostaglandin-Endoperoxide Synthases / drug effects
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Prostaglandins / metabolism
  • Transcription, Genetic / drug effects

Substances

  • CEP-11004
  • Carbazoles
  • Enzyme Inhibitors
  • Indoles
  • Interleukin-6
  • Isoenzymes
  • NF-kappa B
  • Prostaglandins
  • 3,9-bis((ethylthio)methyl)-K-252a
  • Nitric Oxide
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • JNK Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinases
  • MAP Kinase Kinase 4
  • Mitogen-Activated Protein Kinase Kinases